Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 18:18 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Combination Diuretic Therapy for Acute Decompensated Heart Failure
NCT05840536 · Ochsner Health System · PHASE4 · withdrawn · last registry update 2023-05-03 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Ochsner Health System |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SLC12A1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-04-18Results posted on the registry: Melanie Maykin, MD, Furosemide (NCT04615624)
- 2024-03-25Results posted on the registry: Hamilton Health Sciences Corporation, Intravenous albumin + Normal saline (NCT02055872)
- 2024-03-15Results posted on the registry: Vanderbilt University Medical Center, Dapagliflozin 10 MG (NCT04298229)
- 2024-02-09Phase 3 first posted: University Hospital Hradec Kralove, Furosemide 40 mg + Levodropropizine (NCT06252454)
- 2024-01-11Results posted on the registry: University of New Mexico, Bumetanide (NCT02593526)
- 2024-01-11Also stopped (terminated): University of New Mexico, Bumetanide (NCT02593526)
- 2024-01-05Results posted on the registry: National Cardiovascular Center Harapan Kita Hospital Indonesia, Furosemide in 0.9 % NaCl 100 Mg/100 mL (1 mg/mL) + NaCl 0.9% (NCT04919564)
- 2023-12-11Also stopped (terminated): Dr. John Muscedere, Nebulized Furosemide + Nebulized Saline (NCT04588792)
- 2023-11-02Results posted on the registry: PT. Kimia Farma (Persero) Tbk, Furosemide 40 mg + Lasix® 40 mg Tablet (NCT04982874)
- 2023-10-23Results posted on the registry: Wright State University, furosemide + labetalol (NCT04343235)
- 2023-10-23Also stopped (terminated): Wright State University, furosemide + labetalol (NCT04343235)
- 2023-09-14Results posted on the registry: Maruho Co., Ltd., CLS006 + CLS006 Vehicle (NCT03259620)
- 2023-09-14Results posted on the registry: Maruho Co., Ltd., CLS006 (Furosemide) Topical Gel + Vehicle Topical Gel (NCT02971891)
- 2023-08-30Results posted on the registry: Thomas Jefferson University, Furosemide + Placebo (NCT03362515)
- 2023-08-30Also stopped (terminated): Thomas Jefferson University, Furosemide + Placebo (NCT03362515)
- 2023-08-29Also stopped (terminated): Nuwellis, Inc., IV Loop Diuretics (LD) (NCT01474200)
- 2023-08-01Results posted on the registry: scPharmaceuticals, Inc., Furoscix Infusor (NCT04593823)
- 2023-07-27Phase 3 first posted: Wroclaw Medical University, Furosemide intravenous infusion + Continous intravenous infusion of 0.9% Sodium Chloride solution (NCT05962255)
- 2023-07-17Results posted on the registry: Boehringer Ingelheim, BI 730357 + CRESTOR® (NCT04590937)
- 2023-07-11Phase 3 first posted: Tehran University of Medical Sciences, a drug against SLC12A1 (NCT05940220)
- 2023-07-07Results posted on the registry: University of Chicago, Furosemide (NCT01275729)
- 2023-07-06Phase 3 first posted: University of Malaya, Aminophylline + Frusemide (NCT05933642)
- 2023-06-23Phase 3 first posted: University Hospital, Tours, Furosemide 40 mg (NCT05916963)
- 2023-06-05Results posted on the registry: Institut de Recherches Internationales Servier, BUMETANIDE (S95008) for week 0 - 26 + PLACEBO for week 0 - 26 (NCT03715153)
- 2023-06-05Also stopped (terminated): Institut de Recherches Internationales Servier, BUMETANIDE (S95008) for week 0 - 26 + PLACEBO for week 0 - 26 (NCT03715153)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision